Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Overview and Classification
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Dec 26, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Roxana A Lupu1, Heidi Twedt2, Sreekanth Chavour2
1Department of Internal Medicine, University of South Dakota Sanford School of Medicine.
Clinical informatics and genomics advance medicine. Decision support integrating EKG data is needed to manage drug-induced QT prolongation, which can occur without genetic abnormalities.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: